Dr. Xingli Wang

And in that way, we probably would avoid what you call the political issues because we are making the product as a local product.

And we also, for example, making the manufacturing site in Saudi.

It does not say we're not going to do in the long term in the U.S., but we normally say we walk fast with small steps.

In that way, we don't fall.

And by the same planning, our new drug product, the innovative medicine side, when the product is strong, like the PD-1, the subliterumab, we are just completing our U.S.

bridging trial.

And that one we're going to market ourselves in U.S.

by our U.S.

subsidiaries.

So as you can see that our strategy is not like high level approach and top down approach.

We gradually building up so we don't fall.

This is a crystal ball question, right?

Whether it's five or 10 years, but our strategy for future is very clear.

First, we will put most of our attention on drug development.

You know, we have other businesses, for example, we have health care, which our goal is to spin it off to be an independent business.

We have vaccines, it's also a goal to spin it off.

So we're going to focus our Futsal Pharma on the pharmaceutical development first.

Second, we're going to shift 90, more than 90% of our resource on novel drugs rather than established drugs.

Then when we do the novel drugs, we also, as I mentioned to you, we appreciate also understand our capabilities.

So we don't want to overstretch ourselves.